Answers are grounded in this paper and cite their sources.
An innovative, multi-study Phase 3 program to definitively assess safety and efficacy of ulixacaltamide (PRAX-944) in essential tremor (ET).
No takes yet. Share an insight, caveat, or question.
Giroux et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: